Answers are grounded in this paper and cite their sources.
The human DNMT3A gene codes for de novo DNA methyltransferase DNMT3A, and its mutations are often associated with epigenetic disorders in hematological diseases. However, the role of mutations affecting the PWWP domain of the regulatory region of the enzyme is still poorly understood. At the same time, mutations of the PWWP domain can distort the proper DNA methylation pattern and consequently lead to tumor progression. The clinically significant substitutions P307R, R326H, and W409R in the PWWP domain were tested for effect on the isolated PWWP domain and the full-length enzyme with the use of mouse Dnmt3a, which has high homology to human DNMT3A. PWWP-R326H bound DNA more weakly as compared to the wild-type PWWP. In the context of the Dnmt3a2 isoform of the full-length enzyme with removed auto-inhibition (AIR-Dnmt3a2-WT), all variants (P307R, R326H, and W409R) were stable and bound DNA with comparable K d . A key difference was that methylating activity towards a 30-bp DNA substrate differed between the full-length enzymes: AIR-Dnmt3a2-WT, 46 ± 2%; R326H, 23 ± 3%; W409R, 18 ± 1%; and P307R, 2 ± 2%. Therefore, mutations outside the catalytic domain directly reduce the activity of Dnmt3a2. The effects of R326H and W409R are less pronounced, while P307R causes significant dysfunction of the enzyme. The findings are important for characterizing the interaction of mutant DNMT3A with DNA in patients and support the hypothesis that the residues P307, R326, and W409 are essential for the integrity of the PWWP structure and the coordinated function of the regulatory and catalytic domains of the enzyme.
No takes yet. Share an insight, caveat, or question.
Loiko et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: